SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 1, 2021
PMV Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
8 Clarke Drive, Suite 3
Cranbury, New Jersey 08512
(Address, including zip code, of Registrants principal executive offices)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|Common Stock, par value $0.00001 per share||PMVP||The Nasdaq Global Select Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 5.02.|| |
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
(d) Election of Director
On April 1, 2021, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors (the Board) of PMV Pharmaceuticals, Inc. (the Company) unanimously approved the appointment of Charles M. Baum, M.D., Ph.D. as a class II director of the Company to fill the vacancy as a result of the passing of Arnold Oronsky, Ph.D. in November 2020. The effective date of Dr, Baums appointment was April 1, 2021. The term of the Companys class II directors, including Dr. Baum, expires on the date of the Companys annual meeting of the stockholders to be held in 2022 or upon the election and qualification of successor directors.
Dr. Baums compensation will be consistent with that provided to all of the Companys non-employee directors pursuant to the Companys Outside Director Compensation Policy, which was filed as Exhibit 10.15 to the Companys Form 10-K for the year ended December 31, 2020. In addition, the Company entered into an indemnification agreement with Dr. Baum in connection with his appointment to the Board, which is in substantially the same form as that entered into with the other directors of the Company.
There is no arrangement or understanding pursuant to which Dr. Baum was appointed to the Board. There are no family relationships between Dr. Baum and any director or executive officer of the Company, and Dr. Baum has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
|Item 7.01.|| |
Regulation FD Disclosure.
On April 6, 2021, the Company issued a press release announcing Dr. Baums appointment to the Board as discussed in Item 5.02(d) of this Current Report on Form 8-K. The full text of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference to such filing.
|Item 9.01.|| |
Financial Statements and Exhibits.
|99.1||Press Release issued by PMV Pharmaceuticals, Inc., dated April 6, 2021.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|PMV PHARMACEUTICALS, INC.|
Chief Operating Officer and Chief Financial Officer
(Principal Financial and Accounting Officer)
Date: April 6, 2021
PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum
CRANBURY, NJ, April 6, 2021 (GLOBE NEWSWIRE) PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the appointment of Charles M. Baum, M.D., Ph.D., to its Board of Directors.
Chuck is a recognized biopharma leader who has made significant contributions in the advancement of precision oncology, said David Mack, Ph.D., President and Chief Executive Officer of PMV. His strong track record of success in building innovative oncology portfolios, from development through commercial launch, will be an ideal complement to our Board as we navigate our lead candidate, PC14856, through the clinic. We are thrilled to welcome him to the Board and look forward to leveraging his deep expertise in precision therapeutics that target the genetic drivers of cancer as we advance our pipeline of tumor-agnostic p53 reactivators.
Dr. Baum said, PMVs unmatched expertise in p53 biology and innovative approach to precision oncology has the potential, for the first time, to address the most commonly mutated gene in cancer. I am enthusiastic about the Companys platform of small molecules that restore the wild-type function of mutated p53 for targeted, and tumor agnostic, therapies. I am excited to join the Board of PMV and look forward to providing my guidance as the Company continues their execution, both in the clinic and across their development pipeline.
Dr. Baum has served as the President and Chief Executive Officer and as a Board Member of Mirati Therapeutics Inc. since 2012. Under his leadership, Mirati has transformed into a precision oncology company focused on advancing its drug discovery and research and delivering novel therapeutics that target the genetic and immunologic drivers of cancer.
Prior to joining Mirati, Dr. Baum was at Pfizer from 2003 to 2012, most recently as Senior Vice President for Biotherapeutic Clinical Research within Pfizers Worldwide Research & Development division, and prior to that, serving in roles of increasing responsibility, including Vice President, Head of Oncology Development and Chief Medical Officer for Pfizers Biotherapeutics and Bioinnovation Center. He was responsible for the development of Pfizers oncology portfolio, including Inlyta,* Xalkori* and the approval of Sutent.* Prior to Pfizer, Dr. Baum was at Schering-Plough where he was responsible for the Phase I-IV development of several oncology compounds, including Temodar.* Dr. Baum started his career with academic and clinical positions at Stanford and Emory Universities. He currently serves as Chairman of the Board at OncoMyx Therapeutics, Board of Directors member at BCTG Acquisition Corp and on the Scientific Advisory Board at ALX Oncology. He served as a member of the Board of Array Biopharma from 2014 to 2019 when it was acquired by Pfizer and Immunomedics from 2019 to 2020 when it was acquired by Gilead.
Dr. Baum received his M.D. (Medicine) and Ph.D. (Immunology) degrees from Washington University School of Medicine and completed his post-graduate training at Stanford University. Additionally, he has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts and holds a number of patents and patent applications.
Trademarks are property of their respective owners.
p53 plays a pivotal role in preventing abnormal cells from becoming a tumor by inducing programmed cell death. Mutant p53 takes on oncogenic properties that endow cancer cells with a growth advantage and resistance to anti-cancer therapy. The p53 Y220C mutation is associated with many cancers, including but not limited to breast, non-small cell lung cancer, colorectal, pancreatic, and ovarian cancers.
PC14586 is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the crevice present in the p53 Y220C mutant protein, hence, restoring the wild-type, or normal, p53 protein structure and tumor suppressing function. PC14586 is being developed for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.
Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Companys future plans or expectations for PC14586, including expectations regarding the success of its current clinical trial for PC14586; and the future plans or expectations for the Companys discovery platform. Any forward-looking statements in this statement are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.
Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the Companys product candidate development activities and planned clinical trials, the Companys ability to execute on its strategy and operate as an early clinical stage company, the potential for clinical trials of PC14586 or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results, the Companys ability to fund operations, and the impact that the current COVID-19 pandemic will have on the Companys clinical trials, supply chain, and operations, as well as those risks and uncertainties set forth in the section entitled Risk Factors in the Companys Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 3, 2021, and its other filings filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
For Investors and Media:
Chief Financial Officer